Skip to main content Back to Top


Abciximab Injection

Products Affected - Description

    • Reopro intravenous injection, Janssen, 2 mg/mL, 5 mL vial, 1 count, NDC 57894-0200-01 - discontinued

Reason for the Shortage

    • Janssen had Reopro on shortage due to a production interruption at their third party manufacturing site. Janssen is not pursuing new lots of Reopro.
    • There are no other suppliers of abciximab.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Janssen will no longer have Reopro in the US. The last lot expires September 2019.


Updated April 29, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 16, 2018 by Megan Dryer, PharmD. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.